CM Venture Capital Exclusively Leads Pre-A+ Round in Boea Wisdom to Advance Precision Cardiovascular Care
Boea Wisdom’s funding will support research and development, multi-center clinical trials and commercialization of its patient-specific vascular simulation platform.
CM Venture Capital, a science-driven venture capital firm, has exclusively led a multi-million-yuan Pre-A+ round of financing in Boea Wisdom (Hangzhou) Network Technology Co., Ltd. (Boea Wisdom). The funds will be used to accelerate core product R&D, expand multi-center clinical trials, advance commercialization, and strengthen the team—further solidifying the company’s technological leadership in precision interventional vascular solutions.
From Overseas Labs to a Mission-Driven Startup
The company’s journey began in 2019, when a late-night call from a leading vascular surgeon in China reached a group of overseas-based researchers. Despite holding top-tier patents and established careers abroad, the team was moved by the urgent need for more precise cardiovascular diagnostics and treatment in China.
They returned home to found Boea Wisdom, started by four young entrepreneurs. The name nods to that youthful energy: in Chinese, “Boea” sounds like “boys”, while “Wisdom” reflects their commitment to technology-enabled care. Based in Hangzhou, the company integrates engineering simulation, artificial intelligence, and clinical medicine to transform cardiovascular intervention.
Key Milestones
- June 2019: Company established in Hangzhou.
- January 2022: Completed Pre-A round financing.
- November 2023: Received China’s first NMPA Class III medical device certificate for an interventional vascular surgical planning software; launched the core product, DetecMicro®.
- July 2024: Completed the first hospital deployment (the Third Affiliated Hospital of Jilin University), marking initial commercial traction.
- 2025: Expanded to five benchmark hospitals; formed strategic partnerships with Medtronic, Siemens, GE, and other industry leaders; launched a vascular interventional device implantation simulation software and initiated clinical validation with Academician Wang Jian’an’s team.
“Millions of simulations for zero patient risks.”Boea Wisdom
Boea Wisdom combines AI with computational fluid dynamics (CFD), computational solid mechanics (CSM), and patient-specific digital twins to simulate cardiovascular interventions before, during and after a procedure. Its platform supports preoperative planning, intraoperative guidance and postoperative assessment, helping clinicians evaluate treatment options, select suitable stents and simulate their deployment. By collaborating with leading tertiary hospitals, the company aims to make complex vascular interventions safer and more precise, advancing personalized cardiovascular care.
Investor Perspective
CM Venture Capital, the lead investor in this round, is a science-driven venture capital firm deeply rooted in transformative hard tech. Since 2010, it has been active in China’s technology investment landscape, focusing on cutting-edge sectors such as materials and resources, energy and power, as well as digitalization and AI+. Leveraging the expertise of its multinational scientist team, global industrial resources, and a disciplined investment philosophy, CM Venture Capital is consistently committed to providing both capital and strategic support to hard tech businesses.
“Start from what customers actually need, be clear about the value a product must carry and how it lifts value for every party, and define and deliver the product on that basis. This is the principle Boea Wisdom has always held to in product development.”Peidong Qian, CEO, Boea Wisdom
The firm connected with Boea Wisdom through a partnership with L’Oréal, where Boea won the 2024 Big Bang Award for its AI-powered simulation technology. Traditional simulation is time-consuming and computationally heavy, especially for cardiovascular applications. Boea’s core platform, rooted in inverse finite element analysis (i-FEA), a method developed since 2007, features fully self-developed code and delivers faster, more efficient simulations. This opens new commercial opportunities across consumer, industrial, and healthcare applications. In cardiovascular precision care, a field with urgent clinical needs and strong market potential, Boea’s proprietary technology has earned recognition from partners such as Siemens and Medtronic. CM Venture Capital will continue to provide capital and strategic support to help Boea expand its medical and, in due course, non-medical applications.
Looking Ahead
This funding marks a new chapter for Boea Wisdom. The company will continue to deepen its focus on interventional vascular precision solutions, advancing its Detec, Medi, and vascular simulation quality control product lines. On the technology front, it will refine simulation algorithms and digital twin capabilities to expand accuracy and application scope into peripheral vascular and neurointerventional fields. On the commercial front, it will accelerate nationwide multi-center clinical adoption and strengthen partnerships with medical institutions and industry players.
With a steadfast commitment to innovation and purpose, Boea Wisdom aims to become a global leader in digital simulation for cardiovascular care, bringing life-saving precision to patients and clinicians alike.